US alerted to "growing threat" of dengue fever
This article was originally published in Clinica
The US National Institute of Allergy and Infectious Diseases (NIAID) are pouring money into research for diagnostics, vaccines and therapeutics to tackle dengue fever, which is being viewed as a growing threat to US citizens. Early diagnosis and treatment of dengue fever are critical to preventing shock and death, the NIAID says, and it sees the expansion of the medical armoury against the virus as a top priority.
You may also be interested in...
Oxford University/AstraZeneca’s COVID-19 vaccine cuts the spread of the virus by 60%, apart from having 70% efficacy in reducing infections in vaccinated individuals. While that is good news for their Indian partner, Serum Institute, the 90% efficacy shown in a subset due to a dosing error causes a dilemma.
After announcing positive topline Phase II results for its Alzheimer’s candidate late last year, Korea's GemVax releases additional data showing significant improvement in secondary outcomes, further raising expectations for the novel peptide drug.
The US FDA’s decision to ask on device adverse event reports whether the device involved had been serviced by a third party could help the agency as well as device makers, says Ricki Chase, compliance practice director at Lachman Consultant Services.